Access to anti-retroviral drugs, male in Senegal

Senegal: Access to anti-retroviral drugs, male was 56.0% in 2024. ◆ Volatile

Latest (2024)
56.0%
Change on year
up 5.7%
World rank
110th
of 141 countries
All-time high
56.0%
in 2024
All-time low
0.0%
in 2000
Years of data
25
2000–2024

Access to anti-retroviral drugs, male in Senegal, 2000–2024

02040602000201220242000: 0 %2001: 0 %2002: 0 %2003: 0 %2004: 0 %2005: 0 %2006: 0 %2007: 11 %2008: 13 %2009: 16 %2010: 18 %2011: 20 %2012: 19 %2013: 24 %2014: 28 %2015: 33 %2016: 34 %2017: 39 %2018: 44 %2019: 49 %2020: 52 %2021: 52 %2022: 54 %2023: 53 %2024: 56 %

Source: UNAIDS estimates. Measured in %.

Analysis

The most recent figure for access to anti-retroviral drugs, male in Senegal is 56.0%, measured in 2024. That is the highest value across all 25 years on record.

The figure is up 5.7% on the previous year and up 100.0% over ten years.

Over the whole period, access to anti-retroviral drugs, male in Senegal peaked at 56.0% in 2024 and was at its lowest, 0.0%, in 2000.

That places Senegal 110th out of 141 countries with data for 2024, putting it in the bottom quarter.

The series is highly variable year to year, so single readings are best treated with caution.

Access to anti-retroviral drugs, male in Senegal, year by year

Annual values for Access to anti-retroviral drugs, male (%) in Senegal, 2000 to 2024.
Year % Change
2000 0.0%
2001 0.0%
2002 0.0%
2003 0.0%
2004 0.0%
2005 0.0%
2006 0.0%
2007 11.0%
2008 13.0% +18.2%
2009 16.0% +23.1%
2010 18.0% +12.5%
2011 20.0% +11.1%
2012 19.0% -5.0%
2013 24.0% +26.3%
2014 28.0% +16.7%
2015 33.0% +17.9%
2016 34.0% +3.0%
2017 39.0% +14.7%
2018 44.0% +12.8%
2019 49.0% +11.4%
2020 52.0% +6.1%
2021 52.0% +0.0%
2022 54.0% +3.8%
2023 53.0% -1.9%
2024 56.0% +5.7%

Averages by decade

DecadeAverage LowestHighest Years
2000s 4.0% 0.0% 16.0% 10
2010s 30.8% 18.0% 49.0% 10
2020s 53.4% 52.0% 56.0% 5

Countries ranked near Senegal

  1. 109 Barbados 57.0% compare
  2. 110 Niger 56.0% compare
  3. 112 Bahrain 53.0% compare
  4. 113 Angola 52.0% compare
  5. 113 Armenia 52.0% compare
  6. 113 South Sudan 52.0% compare

See the full ranking of 160 places →

More gender data for Senegal

All data for Senegal →

Frequently asked questions

What is access to anti-retroviral drugs, male in Senegal?
Access to anti-retroviral drugs, male in Senegal was 56.0% in 2024, according to UNAIDS estimates.
What is the highest access to anti-retroviral drugs, male recorded in Senegal?
The highest recorded value was 56.0% in 2024.
What is the lowest access to anti-retroviral drugs, male recorded in Senegal?
The lowest recorded value was 0.0% in 2000.
How does Senegal rank for access to anti-retroviral drugs, male?
Senegal ranks 110th out of 141 countries with data for 2024.
Is access to anti-retroviral drugs, male rising or falling in Senegal?
Over the last ten years it is up 100.0%. The long-run trend across the full record is volatile.
Where does this Senegal data come from?
The figures come from UNAIDS estimates, published as part of Access to anti-retroviral drugs, male (%). Statizoid updates them automatically from the source API.

Download this data

CSV · JSON — 25 observations, free to reuse under CC BY 4.0 (World Bank Open Data).

Share, cite or embed this page

Cite this page

Access to anti-retroviral drugs, male in Senegal. Statizoid, drawing on UNAIDS estimates. Retrieved 09 September 2026, from https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-male-percent/senegal/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY 4.0 (World Bank Open Data); please keep the attribution.

<a href="https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-male-percent/senegal/">Access to anti-retroviral drugs, male in Senegal</a> — Statizoid

About this data

Indicator
Access to anti-retroviral drugs, male (%)
Unit
%
Source
UNAIDS estimates
Licence
CC BY 4.0 (World Bank Open Data)
Coverage
160 places, 3,923 data points, 2000–2024
Last refreshed

The percentage of adult males living with HIV who are receiving antiretroviral therapy.